Background:
Patients with rheumatoid arthritis (RA) who respond well to biologics early in treatment tend to have better outcomes. Identifying baseline characteristics that predict early response may facilitate effective patient segmentation and treatment strategies. Objectives: To identify baseline factors that may predict very early low disease activity (LDA) and remission after 1 dose of golimumab (GLM) in patients with active RA in GO-MORE, a study resembling typical clinical practice. Methods: GO-MORE was an open-label, multinational, prospective study in biologic-naïve patients with active RA despite disease-modifying antirheumatic drug (DMARD) therapy. Patients received 50-mg subcutaneous GLM once monthly for 6 months. In post hoc analyses, potential baseline predictors of LDA (28-joint disease activity score using erythrocyte sedimentation rate [DAS28-ESR] ≤3.2) after 1 month (1 dose) were first evaluated in univariate models. Factors were evaluated in a stepwise fashion; those with significant associations (P<.10) were included in a final multivariate model. A similar analysis procedure evaluated predictors of achievement of remission (DAS28-ESR <2.6) after 1 month of treatment. Results: At baseline in 3280 efficacy-evaluable patients (82.8% female), mean age was 52.3 years, mean disease duration was 7.6 years, and mean DAS28-ESR was 5.97 (SD=1.095). After 1 month of GLM treatment, 16.6% (545/3280) of patients achieved LDA, and 7.7% (251/3280) achieved remission. 
